DREAMM5

Platform Study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination with Anti-Cancer Treatments in Participants with Relapsed/Refractory Multiple Myeloma (RRMM)

Arms / Cohorts

Comparator Arm:Belantamab Mafodotin

Accepting patients

Sub-study 1, Dose Expansion:Belantamab Mafodotin + GSK3174998

Accepting patients

Sub-study 2, Dose Expansion:Belantamab Mafodotin + Feladilimab

Accepting patients

Sub-study 3, Dose Expansion:Belantamab Mafodotin + Nirogacestat

Accepting patients

Sub-study 4, Dose Expansion:Belantamab Mafodotin + Dostarlimab

Accepting patients

Sub-study 5, Dose Expansion:Belantamab Mafodotin + Isatuximab

Accepting patients

Sub-study 6, Dose Expansion:Belantamab Mafodotin + Nirogacestat + Lenalidomide + Dexamethasone

Accepting patients

Sub-study 7, Dose Expansion:Belantamab Mafodotin + Nirogacestat + Pomalidomide + Dexamethasone

Accepting patients

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 850-0650

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.